Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05396248 · ClinicalTrials.gov registry record · NA

Improve New Learning and Memory in Individuals With Mild Cognitive Impairment

A NA study of Mild Cognitive Impairment, sponsored by Kessler Foundation.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
2
Study locations

NCT05396248: Recruiting NA study of Mild Cognitive Impairment, sponsored by Kessler Foundation.

NCT05396248 is a NA study of Mild Cognitive Impairment that is actively recruiting participants, run by Kessler Foundation. The registered enrollment target is 120 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05396248, a NA study of Mild Cognitive Impairment, is actively recruiting participants, sponsored by Kessler Foundation.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
2
Study locations

Study Summary

The current study is a double-blind, placebo-control randomized clinical trial examining the efficacy of memory retraining in individuals with Mild Cognitive Impairment (MCI). Impairment in higher level cognitive processing, such as new learning and memory, is one of the most common deficits in individuals with MCI and such deficits have been shown to exert significant negative impact on multiple aspects of everyday life, including occupational and social functioning. Despite these findings, few studies have attempted to treat these cognitive deficits in order to improve the everyday functioning of individuals with MCI. Through a small randomized clinical trial, the investigators found that individuals with MCI with documented cognitive impairment show a significant improvement in their memory performance following a treatment protocol designed to facilitate learning. The current proposal will replicate this finding and further evaluate (a) the impact of the treatment on everyday functioning, (b) the long term efficacy of the treatment and (c) the utility of booster sessions in facilitating long-term treatment effects. We will randomly assign older individuals who meet criteria for a diagnosis of amnestic MCI to a memory retraining group or a placebo control group. Both groups will undergo baseline, immediate and long-term follow-up assessment consisting of: (1) a traditional neuropsychological battery, (2) an assessment of global functioning examining the impact of the treatment on daily activities, and (3) functional neuroimaging. This design will allow the investigators to evaluate the efficacy of this particular memory retraining technique in an aMCI population through the assessment of cognitive function via a standard evaluation. In addition, the investigators will be able to draw conclusions regarding the impact of this particular memory remediation program on everyday life from questionnaires completed by the participant and a significant other. Optional enr

Primary Outcome

Change in total score from Open-Trial Selective Reminding Test (OT-SRT)

Conditions Studied

Interventions

  • BEHAVIORAL Memory Retraining Exercises
  • BEHAVIORAL Placebo Control Memory Exercises

Study Locations (2)

Michigan

  • University of Michigan - Ann Arbor

New Jersey

  • Kessler Foundation Research Center - West Orange

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-06-28
Est. Completion 2027-03
Phase NA
Kessler Foundation

104 total trials

What NCT05396248 shows while recruiting

NCT05396248 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Memory Retraining Exercises is the first listed.

NCT05396248 reports a single indexed study location in Michigan, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05396248 about?

NCT05396248 is a clinical study titled "Improve New Learning and Memory in Individuals With Mild Cognitive Impairment". The current study is a double-blind, placebo-control randomized clinical trial examining the efficacy of memory retraining in individuals with Mild Cognitive Impairment (MCI). Impairment in higher level cognitive processing, such as new learning and memory, is one of the most common deficits in indi...

What is the current status of trial NCT05396248?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-06-28. Estimated completion is 2027-03.

What conditions does trial NCT05396248 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment.

What interventions are being tested in trial NCT05396248?

The interventions under investigation include: Memory Retraining Exercises (BEHAVIORAL), Placebo Control Memory Exercises (BEHAVIORAL).

Who is sponsoring clinical trial NCT05396248?

This trial is sponsored by Kessler Foundation, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05396248 being conducted?

This trial has 2 study locations across Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05396248's enrollment target sits among peer trials

120 79th of 205 higher than 122 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05396248, the US trial registry maintained by the National Library of Medicine. NCT05396248 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.